The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease

Background: There is an ongoing debate if and how kidney and liver volume are associated with pain and gastrointestinal (GI) symptoms in autosomal dominant polycystic kidney disease (ADPKD) patients. Since both kidney and liver volume could interact, we investigated whether combined total kidney and liver volume had stronger associations with ADPKD-related pain and GI symptoms than the volumes of the organs separately. Methods: We used baseline data from the DIPAK-1 study, which included ADPKD patients with an estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min/1.73 m2. MR imaging was performed to measure height-adjusted total kidney volume (hTKV), height-adjusted total liver volume (hTLV) and the combination of both (height-adjusted total kidney liver volume [hTKLV]). Results: Three hundred nine ADPKD patients were included with a mean age of 48 ± 7 years, 53% female, eGFR 50 ± 11 mL/min/1.73 m2 and median hTKV, hTLV and hTKLV of 1,095 (758-1,669), 1,173 (994-1,523) and 2,496 (1,972-3,352) mL/m, respectively. ADPKD-related pain and GI symptoms were present in, respectively, 27.5 and 61.2% of patients. Gender was no effect modifier in the association between kidney and/or liver volume, and symptom burden, indicating that all models could be tested in the overall study population. hTKLV and hTLV were significantly associated with pain and GI symptoms, whereas hTKV was not. Model testing revealed that the associations of pain and GI symptoms with hTKLV were significantly stronger than with hTKV (p = 0.04 and p = 0.04, respectively) but not when compared to hTLV (p = 0.2 and p = 0.5, respectively). Conclusions: This study indicates that combined kidney and liver volume was associated with the presence and severity of pain and GI symptoms in ADPKD, with a more prominent role for hTLV than for hTKV.

[1]  Hyo Sang Kim,et al.  Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease , 2015, PloS one.

[2]  B. Kasiske,et al.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2015, Kidney international.

[3]  R. Monshouwer,et al.  Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[4]  F. Nevens,et al.  Evaluating health‐related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[5]  R. Gansevoort,et al.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  J. D. de Fijter,et al.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Kaleab Z. Abebe,et al.  Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  B. Kerr,et al.  The transition from acute to chronic pain: understanding how different biological systems interact , 2014, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[9]  Luca Antiga,et al.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial , 2013, The Lancet.

[10]  Y. Ubara,et al.  Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study , 2013, BMC Nephrology.

[11]  M. V. van Oijen,et al.  Gastrointestinal Symptoms are Still Prevalent and Negatively Impact Health-Related Quality of Life: A Large Cross-Sectional Population Based Study in The Netherlands , 2013, PloS one.

[12]  R. Fillingim,et al.  Sex differences in pain: a brief review of clinical and experimental findings. , 2013, British journal of anaesthesia.

[13]  J. Drenth,et al.  Diagnosis and management of polycystic liver disease , 2013, Nature Reviews Gastroenterology &Hepatology.

[14]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[15]  C. Kalkman,et al.  Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. , 2011, British journal of anaesthesia.

[16]  J. Grantham,et al.  Why kidneys fail in autosomal dominant polycystic kidney disease , 2011, Nature Reviews Nephrology.

[17]  M. V. van Oijen,et al.  Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[18]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[19]  L. Antiga,et al.  Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[20]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[21]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[22]  C. Jurkovitz,et al.  Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[23]  M. Numans,et al.  Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial , 2009, The Lancet.

[24]  P K Commean,et al.  Volumetric Measurement of Renal Cysts and Parenchyma Using MRI: Phantoms and Patients with Polycystic Kidney Disease , 2000, Journal of computer assisted tomography.

[25]  Kaleab Z. Abebe,et al.  Liver involvement in early autosomal-dominant polycystic kidney disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  Bradley J Erickson,et al.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.

[27]  A. Paterson,et al.  Unified criteria for ultrasonographic diagnosis of ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.

[28]  F. Windmeijer,et al.  R-Squared Measures for Count Data Regression Models With Applications to Health-Care Utilization , 1996 .